Oncology Based In-Vivo CRO Business Research Report 2024: Global Market To Reach $2.5 Billion By 2030 - Expansion In Drug Discovery, Translational Research, And Toxicology Fuels Growth

(MENAFN- GlobeNewsWire - Nasdaq) Understand the significant growth trajectory of the Solid Tumors Indication segment, which is expected to reach US$1.2 Billion by 2030 with a CAGR of a 6.9%. The Blood Cancer Indication segment is also set to grow at 5.8% CAGR over the analysis period. Gain insights into the U.S. market, estimated at $421.9 Million in 2023, and China, forecasted to grow at an impressive 6.5% CAGR to reach $383.5 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Dublin, Jan. 09, 2025 (GLOBE NEWSWIRE) -- The "Oncology Based in-Vivo CRO - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
The global market for Oncology Based In-Vivo CRO was estimated at US$1.5 Billion in 2023 and is projected to reach US$2.5 Billion by 2030, growing at a CAGR of 7.0% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Oncology-based In-Vivo Contract Research Organizations (CROs) provide specialized services for preclinical testing of cancer therapies in live animal models. These CROs offer comprehensive in-vivo studies, including pharmacology, toxicology, and efficacy assessments, enabling pharmaceutical and biotech companies to evaluate the potential of new cancer drugs before clinical trials. By utilizing animal models that mimic human cancer conditions, CROs help researchers understand drug behavior, dosage optimization, and side effects.

The growing complexity of cancer treatments, which now include immunotherapies, targeted therapies, and gene therapies, has increased the demand for specialized in-vivo studies to ensure safety and efficacy.

What Factors Are Driving the Growth in the Oncology Based In-Vivo CRO Market?
The growth in the Oncology Based In-Vivo CRO market is driven by several factors, including the increasing prevalence of cancer, which has fueled demand for new therapies and accelerated drug development. The shift toward targeted and personalized treatments, such as immunotherapies and gene therapies, has necessitated the use of specialized in-vivo models that accurately mimic human tumors.

Advancements in preclinical research tools, such as imaging techniques and biomarker analysis, have improved study accuracy and efficiency, supporting broader adoption. The rise in collaborations between CROs and biopharma companies, along with increased government funding for cancer research, has further contributed to market growth. Additionally, the growing number of biotech startups focused on innovative oncology therapies has boosted demand for in-vivo CRO services.

What Are the Key Segments in the Oncology Based In-Vivo CRO Market?
Key services include pharmacokinetics (PK), pharmacodynamics (PD), toxicology, and efficacy testing, with pharmacokinetics and pharmacodynamics being the most in-demand services due to their importance in early-stage drug development. The application segment covers different cancer types, such as lung cancer, breast cancer, colorectal cancer, and blood cancers, with lung and breast cancer studies accounting for a significant share due to their high prevalence and active drug development pipelines. Major end-users include pharmaceutical companies, biotechnology firms, and academic research institutions, all of which rely on in-vivo CROs to advance their oncology drug discovery efforts.
How Are In-Vivo CROs Integrated Into Oncology Research?
Pharmaceutical companies collaborate with in-vivo CROs to conduct preclinical testing for new cancer treatments, reducing the time and cost associated with drug development. These CROs offer tailored in-vivo models, including patient-derived xenografts (PDX), syngeneic models, and transgenic models, to accurately represent human tumor biology. Biotechnology firms, often focusing on novel therapies like CAR-T cells and bispecific antibodies, use in-vivo CROs for efficacy and safety evaluations before moving to clinical trials.

Academic and research institutions also work with CROs to study the mechanisms of action of potential cancer therapies and identify promising drug candidates. The integration of advanced technologies, such as imaging tools and biomarker analysis, has enhanced the accuracy and relevance of in-vivo studies in oncology research.

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of major players in the Global Oncology Based In-Vivo CRO Market such as Champion Oncology, Inc., Charles River Laboratory, Covance, Crown Bioscience, Eurofins Scientific and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Key Attributes:

Report Attribute	Details
No. of Pages	93
Forecast Period	2023 - 2030
Estimated Market Value (USD) in 2023	$1.5 Billion
Forecasted Market Value (USD) by 2030	$2.5 Billion
Compound Annual Growth Rate	7.0%
Regions Covered	Global

Key Topics Covered:
MARKET OVERVIEW

• Influencer Market Insights
• World Market Trajectories
• Global Economic Update
• Oncology Based In-Vivo CRO - Global Key Competitors Percentage Market Share in 2024 (E)
• Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)

MARKET TRENDS & DRIVERS

• Rising Demand for Cancer Research Spurs Growth in Oncology-Based In-Vivo CRO Market
• Technological Advancements in Preclinical Models and Imaging Strengthen Business Case for Adoption
• Growing Focus on Personalized Medicine and Immuno-Oncology Expands Addressable Market
• Expansion of In-Vivo CROs in Drug Discovery, Translational Research, and Toxicology Fuels Market Growth
• Increasing Adoption of In-Vivo Models in Target Validation, Biomarker Identification, and Efficacy Studies Expands Market Opportunities
• Technological Innovations in Animal Models, Xenografts, and Patient-Derived Tumor Models Propel Market Expansion
• Growing Use of In-Vivo CROs in Cell Therapy, Gene Therapy, and Antibody-Drug Conjugates (ADCs) Expands Market Potential
• Focus on Achieving Faster Time-to-Market for New Therapies Strengthens Market for Oncology-Based In-Vivo CRO
• Technological Advancements in High-Throughput Screening, Genomics, and Imaging Propel Market Growth
• Increasing Focus on Integrating In-Vivo CROs with Big Data Analytics and Real-Time Monitoring Drives Adoption
• Rising Demand for In-Vivo CRO Services in Immuno-Oncology, Radiotherapy, and CAR-T Therapy Strengthens Global Market
• Expansion of Oncology-Based In-Vivo CROs in Rare Cancers, Pediatric Oncology, and Early-Phase Trials Expands Market Opportunities

FOCUS ON SELECT PLAYERS: Some of the 42 companies featured in this Global Oncology Based In-Vivo CRO market report include

• Champion Oncology, Inc.
• Charles River Laboratory
• Covance
• Crown Bioscience
• Eurofins Scientific
• EVOTEC
• ICON Plc
• Living Tumor Laboratory
• MI Bioresearch, Inc.
• Taconic Biosciences
• The Jackson Laboratory
• Wuxi AppTec
• Xentech

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment

• Oncology Based in-Vivo CRO Market

CONTACT: CONTACT: Laura Wood,Senior Press Manager ... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN09012025004107003653ID1109071612